Comparable stake leader
Ikarian Capital, LLC
SEC ownership of Quoin Pharmaceuticals, Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671502.
Disclosed value leader
Stonepine Capital Management, LLC
Comparable rows
26/33
Latest evidence
26 May 2026
- Public ticker
- QNRX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ikarian Capital, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 33
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Ikarian Capital, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
26 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001671502
- Issuer location
- Kfar Saba
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Quoin Pharmaceuticals, Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Stonepine Capital Managem...
Comparable rows
26/33
Latest evidence
26 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 13%
7 rows are not safely comparable across share classes.
13D/G row: Ikarian Capital, LLC
Showing 1-8 of 33 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 13%.
26 of 33 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
13%
Stonepine Capital Management, LLC
11%
Woodline Partners LP
9.5%
Resolute Capital Asset Partners LLC
8.5%
INTEGRATED CORE STRATEGIES (US) LLC
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 33 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
Company
|
13%
|
$3,052,472
211,538 shares
|
$0 | 31 Jan 2026 |
| Stonepine Capital Management, LLC |
3/4/5
13D/G
13F
10%+ Owner · Company
|
11%
from 13D/G
|
$47,201,973
3,271,100 shares
|
— | 26 Mar 2026 |
| Woodline Partners LP |
13D/G
13F
Company
|
9.5%
|
$38,298,838
2,785,370 shares
|
$0 | 31 Dec 2025 |
| Resolute Capital Asset Partners LLC |
13D/G
|
8.5%
|
$671,000
50,000 shares
|
$0 | 10 Oct 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
5.5%
|
$22,755,775
3,850,385 shares
|
+$7,279,879 | 26 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$7,049,313
1,081,183 shares
|
$0 | 31 Mar 2025 |
| ADAR1 Capital Management, LLC |
13D/G
ADAR1 Capital Management GP, LLC
|
4.9%
|
$609,067
102,883 shares
|
+$264,346 | 31 Mar 2026 |
| Denise P. Carter |
13D/G
3/4/5
Denise Carter · Chief Operating Officer, Director
|
4.9%
|
$244,202
939,238 shares
|
+$82,374 | 27 Jan 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$128,640.
Buys
$128,640
Insiders: 1
Sells
$0
Insiders: 0
Net
+$128,640
Shares: +15,152
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 15,152
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 15,152 | 0 | $128,640 | $0 | +$128,640 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Quoin Pharmaceuticals, Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Stonepine Capital Management, LLC
Net 12M change
+$128,640
Latest report
26 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 10%+ Owner | $47,201,973 | Mixed | 26 Mar 2026 | ||
| Dennis Langer | Director | $128,648 | +$128,640 | +1608000% | Filing P/S | 04 Feb 2026 |
| Gordon Dunn | Chief Financial Officer | $67,985 | Filing P/S | 23 Dec 2024 | ||
| Sember Michael T. | Director | Mixed | 04 Feb 2026 | |||
| Natalie Ee Mun Leong | Director | Mixed | 04 Feb 2026 | |||
| Joseph Patrick Cooper | Director | Mixed | 04 Feb 2026 | |||
| Anthony James Culverwell | Director | Mixed | 04 Feb 2026 | |||
| Michael Myers | Chief Executive Officer, Director | Mixed | 04 Feb 2026 | |||
| Denise P. Carter | Chief Operating Officer, Director | Mixed | 04 Feb 2026 | |||
| Sally Bridget Lawlor | Chief Financial Officer | Mixed | 04 Feb 2026 |
Recent insider transactions for Quoin Pharmaceuticals, Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sally Bridget Lawlor | QNRX | Share Option (Right to Buy) | Award | 85,250 | 85,250 | 04 Feb 2026 | Direct | |||
| Joseph Patrick Cooper | QNRX | Share Option (Right to Buy) | Award | 8,141 | 8,141 | 04 Feb 2026 | Direct | |||
| Anthony James Culverwell | QNRX | Share Option (Right to Buy) | Award | 21,709 | 21,709 | 04 Feb 2026 | Direct | |||
| Michael Myers | QNRX | Share Option (Right to Buy) | Award | 318,750 | 318,750 | 04 Feb 2026 | Direct | |||
| Denise P. Carter | QNRX | Share Option (Right to Buy) | Award | 318,750 | 318,750 | 04 Feb 2026 | Direct | |||
| Dennis Langer | QNRX | Share Option (Right to Buy) | Award | 21,709 | 21,709 | 04 Feb 2026 | Direct | |||
| Sember Michael T. | QNRX | Share Option (Right to Buy) | Award | 8,141 | 8,141 | 04 Feb 2026 | Direct | |||
| Natalie Ee Mun Leong | QNRX | Share Option (Right to Buy) | Award | 12,211 | 12,211 | 04 Feb 2026 | Direct | |||
| Sally Bridget Lawlor | QNRX | Share Option (Right to Buy) | Award | 10,330 | 10,330 | 01 Dec 2025 | Direct | |||
| Dennis Langer | QNRX | ADSs | Purchase | 1515200% | $128,640 | $8.49 | 15,152 | 15,153 | 14 Oct 2025 | Direct |
| Dennis Langer | QNRX | Series K Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series J Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series I Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series H Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Natalie Ee Mun Leong | QNRX | Share Option (Right to Buy) | Award | 4,105 | 4,105 | 21 Aug 2025 | Direct | |||
| Anthony James Culverwell | QNRX | Share Option (Right to Buy) | Award | 13,682 | 13,682 | 21 Aug 2025 | Direct | |||
| Dennis Langer | QNRX | Share Option (Right to Buy) | Award | 13,682 | 13,682 | 21 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.